SEROFLO CIPHALER 250/50 fluticasone propionate/salmeterol 250/50 mcg/dose inhalation powder pre-dispensed BP plastic inhaler

Land: Australia

Språk: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Aktiv ingrediens:

salmeterol xinafoate, Quantity: 0.0725 mg; fluticasone propionate, Quantity: 0.25 mg

Tilgjengelig fra:

Cipla Australia Pty Ltd

Legemiddelform:

Inhalation, powder for

Sammensetning:

Excipient Ingredients: lactose monohydrate

Administreringsrute:

Inhalation

Indikasjoner:

For the regular treatment of asthma, where the use of a combination product is appropriate. This may include ? Patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? Patients who are symptomatic on current inhaled corticosteroid therapy For the symptomatic treatment of patients with severe COPD (FEV1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. SEROFLO CIPHALER 250/50 is not indicated for the initiation of bronchodilator therapy in COPD.

Produkt oppsummering:

Visual Identification: Salmeterol/fluticasone propionate inhalation powder, pre-dispensed BP, is a white to off white powder filled in a strip of 60 blisters; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Autorisasjon status:

Registered

Autorisasjon dato:

2021-08-12